FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736451355> ?p ?o ?g. }

• W2736451355 abstract "Vinflunine is the only chemotherapeutic agent shown to improve survival in platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium (TCCU) in a phase III clinical trial, which led to product registration for this indication in Europe. The aim of this study was to assess the efficacy of vinflunine and to evaluate the prognostic significance of risk factors in a large, unselected cohort of patients with metastatic TCCU treated according to routine clinical practice.This was a retrospective multicenter study. Italian cancer centers were selected if, according to the Registry of the Italian Medicines Agency (AIFA), at least four patients had been treated with vinflunine between February 2011 and June 2014, after first- or second-line platinum-based chemotherapy. The primary objective was to test whether the efficacy measured by overall survival (OS) in the registration study could be confirmed in routine clinical practice. Multivariate analysis was carried out using Cox proportional hazard model.A total of 217 patients were treated in 28 Italian centers. Median age was 69 years (IQR 62-76) and 84% were male; Eastern Cooperative Oncology Group performance status (ECOG PS) was ≥ 1 in 53% of patients. The median number of cycles was 4 (IQR 2-6); 29%, 35%, and 36% received an initial dose of 320 mg/m2, 280 mg/m2 or a lower dose, respectively. Median progression-free survival (PFS) and OS for the entire population was 3.2 months (2.6-3.7) and 8.1 months (6.3-8.9). A complete response was observed in six patients, partial response in 21, stable disease in 60, progressive disease in 108, with a disease control rate of 40%. Multivariate analysis showed that ECOG PS, number of metastatic sites and liver involvement were unfavorable prognostic factors for OS. Toxicity was mild, and grade 3-4 adverse effects were mainly: neutropenia (9%), anemia (6%), asthenia/fatigue (7%) and constipation (5%).In routine clinical practice the results obtained with VFL seem to be better than the results of the registration trial and reinforce evidence supporting its use after failure of a platinum-based chemotherapy." @default.
• W2736451355 created "2017-07-31" @default.
• W2736451355 creator A5007414606 @default.
• W2736451355 creator A5011322435 @default.
• W2736451355 creator A5023171492 @default.
• W2736451355 creator A5025009832 @default.
• W2736451355 creator A5041135391 @default.
• W2736451355 creator A5041597689 @default.
• W2736451355 creator A5045450050 @default.
• W2736451355 creator A5048165263 @default.
• W2736451355 creator A5051919018 @default.
• W2736451355 creator A5052289386 @default.
• W2736451355 creator A5053521368 @default.
• W2736451355 creator A5059367989 @default.
• W2736451355 creator A5060297610 @default.
• W2736451355 creator A5062532607 @default.
• W2736451355 creator A5067193136 @default.
• W2736451355 creator A5071060598 @default.
• W2736451355 creator A5071606172 @default.
• W2736451355 creator A5083659627 @default.
• W2736451355 creator A5084034066 @default.
• W2736451355 creator A5084629809 @default.
• W2736451355 date "2017-07-19" @default.
• W2736451355 modified "2023-10-17" @default.
• W2736451355 title "Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)" @default.
• W2736451355 cites W1556232272 @default.
• W2736451355 cites W1968252785 @default.
• W2736451355 cites W1985014438 @default.
• W2736451355 cites W1998119353 @default.
• W2736451355 cites W2041435757 @default.
• W2736451355 cites W2101562875 @default.
• W2736451355 cites W2102116016 @default.
• W2736451355 cites W2105737543 @default.
• W2736451355 cites W2107435378 @default.
• W2736451355 cites W2113101214 @default.
• W2736451355 cites W2132379894 @default.
• W2736451355 cites W2135889186 @default.
• W2736451355 cites W2154029052 @default.
• W2736451355 cites W2235523093 @default.
• W2736451355 cites W2289712604 @default.
• W2736451355 cites W2301470659 @default.
• W2736451355 cites W2313972367 @default.
• W2736451355 cites W2334797339 @default.
• W2736451355 cites W23441172 @default.
• W2736451355 cites W2347172153 @default.
• W2736451355 cites W2463010142 @default.
• W2736451355 cites W2485263088 @default.
• W2736451355 cites W2521069124 @default.
• W2736451355 cites W4313635027 @default.
• W2736451355 doi "https://doi.org/10.1186/s12885-017-3466-3" @default.
• W2736451355 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5517798" @default.
• W2736451355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28724419" @default.
• W2736451355 hasPublicationYear "2017" @default.
• W2736451355 type Work @default.
• W2736451355 sameAs 2736451355 @default.
• W2736451355 citedByCount "6" @default.
• W2736451355 countsByYear W27364513552018 @default.
• W2736451355 countsByYear W27364513552019 @default.
• W2736451355 countsByYear W27364513552020 @default.
• W2736451355 countsByYear W27364513552021 @default.
• W2736451355 crossrefType "journal-article" @default.
• W2736451355 hasAuthorship W2736451355A5007414606 @default.
• W2736451355 hasAuthorship W2736451355A5011322435 @default.
• W2736451355 hasAuthorship W2736451355A5023171492 @default.
• W2736451355 hasAuthorship W2736451355A5025009832 @default.
• W2736451355 hasAuthorship W2736451355A5041135391 @default.
• W2736451355 hasAuthorship W2736451355A5041597689 @default.
• W2736451355 hasAuthorship W2736451355A5045450050 @default.
• W2736451355 hasAuthorship W2736451355A5048165263 @default.
• W2736451355 hasAuthorship W2736451355A5051919018 @default.
• W2736451355 hasAuthorship W2736451355A5052289386 @default.
• W2736451355 hasAuthorship W2736451355A5053521368 @default.
• W2736451355 hasAuthorship W2736451355A5059367989 @default.
• W2736451355 hasAuthorship W2736451355A5060297610 @default.
• W2736451355 hasAuthorship W2736451355A5062532607 @default.
• W2736451355 hasAuthorship W2736451355A5067193136 @default.
• W2736451355 hasAuthorship W2736451355A5071060598 @default.
• W2736451355 hasAuthorship W2736451355A5071606172 @default.
• W2736451355 hasAuthorship W2736451355A5083659627 @default.
• W2736451355 hasAuthorship W2736451355A5084034066 @default.
• W2736451355 hasAuthorship W2736451355A5084629809 @default.
• W2736451355 hasBestOaLocation W27364513551 @default.
• W2736451355 hasConcept C126322002 @default.
• W2736451355 hasConcept C143998085 @default.
• W2736451355 hasConcept C207103383 @default.
• W2736451355 hasConcept C2780140570 @default.
• W2736451355 hasConcept C2908647359 @default.
• W2736451355 hasConcept C44249647 @default.
• W2736451355 hasConcept C50382708 @default.
• W2736451355 hasConcept C535046627 @default.
• W2736451355 hasConcept C71924100 @default.
• W2736451355 hasConcept C72563966 @default.
• W2736451355 hasConcept C99454951 @default.
• W2736451355 hasConceptScore W2736451355C126322002 @default.
• W2736451355 hasConceptScore W2736451355C143998085 @default.
• W2736451355 hasConceptScore W2736451355C207103383 @default.
• W2736451355 hasConceptScore W2736451355C2780140570 @default.
• W2736451355 hasConceptScore W2736451355C2908647359 @default.
• W2736451355 hasConceptScore W2736451355C44249647 @default.
• W2736451355 hasConceptScore W2736451355C50382708 @default.

• next